Novartis India Limited (BOM: 500672)
India
· Delayed Price · Currency is INR | Market Cap | 26.21B |
| Revenue (ttm) | 3.45B |
| Net Income (ttm) | 874.00M |
| Shares Out | 24.69M |
| EPS (ttm) | 35.39 |
| PE Ratio | 29.99 |
| Forward PE | n/a |
| Dividend | 25.00 (2.36%) |
| Ex-Dividend Date | Jul 23, 2024 |
| Volume | 8,480 |
| Open | 1,062.00 |
| Previous Close | 1,072.80 |
| Day's Range | 1,051.05 - 1,079.95 |
| 52-Week Range | 671.75 - 1,248.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 25, 2024 |
About Novartis India
Novartis India Limited operates as a healthcare company in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neurosciences products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is based in Mumbai, India. The company is a subsidiary of Novartis AG. [Read more]
Financial Performance
In 2023, Novartis India's revenue was 3.35 billion, a decrease of -11.53% compared to the previous year's 3.79 billion. Earnings were 851.90 million, a decrease of -17.58%.
Financial StatementsNews
Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition
Novartis India (BSE: ₹1,181.70) surged 8.95% in intraday trading at 3:02 PM, following reports by CNBC-TV18 indicating that Alkem Labs is in talks to acquire the company from its Swiss parent, Novarti...